In this role, Ms. Roxland re-launched and chaired J&J's Ethics Committee, created an enterprise - wide
consultation service for teams and individuals confronting complex research ethics issues, and provided guidance on issues such as post-trial access for former research
participants, conducting clinical trials in war - torn regions, testing of a potential Ebola vaccine
during a public health crisis, commercialization of stem cell therapies, subject recruitment and withdrawal, and expanded access / compassionate use.